Please provide your email address to receive an email when new articles are posted on . Addressing nonculprit lesions during primary PCI for STEMI was noninferior vs. a staged strategy. The trial was ...

Epigenetic inactivation of HOXA5 and MSH2 gene in clear cell renal cell carcinoma. Background: Primary lesion in mRCC often shows necrotic change or only density changes to targeted therapy. As most ...

NEW ORLEANS ― In more than 10% of cases in which ductal carcinoma in situ (DCIS) recurs in the same breast, the new lesion is genetically distinct from the original lesion, according to a study ...

DermaSensor announced newly published studies supporting the performance of its device for evaluating suspicious skin lesions ...

In January, after the DermaSensor became the first artificial intelligence (AI)-enabled device cleared by the US Food and Drug Administration (FDA) to evaluate lesions suggestive of skin cancer, the ...

NEW ORLEANS – More than 10 percent of cases of recurrent ductal carcinoma in situ (DCIS) of the breast were “de novo” tumors that occurred independently of the primary lesion and had distinct genetic ...

Please provide your email address to receive an email when new articles are posted on . A substantial portion of ductal carcinoma in situ recurrences did not appear genetically related to their ...

CANKADO PRO-React eHealth support in patients with HR+ HER2- metastatic breast cancer receiving palbociclib and endocrine therapy and the affect on time to deterioration of quality of life: Primary ...

The combination of Padcev and Keytruda showed promising clinical activity in UTUC patients, with a 25% ORR in primary lesions and 35% in target lesions. The study included 22 patients with intact ...